BioSpace News Archive

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the appointment of Mimi Guarneri, MD, FACC

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) to Gilead Sciences, Inc. (Nasdaq: GILD),

The overdose crisis continues to affect communities and families across Canada. Tragically, we have seen significant increases in overdose deaths and related harms during the COVID-19 pandemic, including in Toronto where overdoses deaths increased significantly between January 1 and November 30 last year.

Today, AMRA Medical announced an expansion of its dataset, resulting from a collaboration with Pfizer Inc. and UK Biobank, from 10,000 to 25,000 UK Biobank participants – another step toward their shared goal of analyzing the body composition of 100,000 individuals

InnerScope’s CEO will be featured in a 12-Part series of interviews on NEWSMAX Television “New To The Street” syndicated television show which airs on Sundays at 10 AM EST, and broadcasts across three major US Television Networks to over 540 million homes in the US and international markets

Aura Biosciences Announces Publication of Data in Cancer Immunology Research , Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment - Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity -

ThermoTek, Inc. (“ThermoTek”), a portfolio company of private equity firm Havencrest Capital Management, announced today the hiring of Randy D. Chatman as its new Chief Executive Officer

Remains on Track to Dose First Subjects in Q2 2021.

MitoChem Therapeutics, Inc. , a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to its lead compound, MC16, for treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is an inherited degenerative disease of the retina caused by genetic mutations that lead to severe vision loss and blindness

Health Canada is updating Canadians and healthcare professionals about its ongoing safety review of very rare events of blood clots associated with low levels of blood platelets following immunization with the AstraZeneca and COVISHIELD COVID-19 vaccines.